Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017

Diabetes, Obesity and Metabolism

Volumn 20, Issue 9, 2018, Pages 2159-2168

  Curtis, Helen J ^a   Dennis, John M ^b   Shields, Beverley M ^b   Walker, Alex J ^a   Bacon, Seb ^a   Hattersley, Andrew T ^b   Jones, Angus G ^b   Goldacre, Ben ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

Author keywords

antidiabetic drug; cost effectiveness; glycaemic control; primary care; type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; METFORMIN; PRESCRIPTION DRUG; SODIUM GLUCOSE COTRANSPORTER 1 INHIBITOR; SULFONYLUREA; SULFONYLUREA DERIVATIVE;

ARTICLE; CLINICAL PRACTICE RESEARCH DATALINK; CONTROLLED STUDY; DATA BASE; DRUG CLASSIFICATION; DRUG COST; GENERAL PRACTICE; GEOGRAPHIC MAPPING; GEOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRESCRIPTION; TIME TREND; TREND STUDY; ENGLAND; FACTUAL DATABASE; MEDICAL GEOGRAPHY; SUPPLY AND DISTRIBUTION; TIME;

DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENGLAND; GEOGRAPHY, MEDICAL; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; SULFONYLUREA COMPOUNDS; TIME;

EID: 85051189013     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13346     Document Type: Article

References (33)

1. NHS-England. QOF 2015–16. http://www.content.digital.nhs.uk/searchcatalogue?productid=23378&q=qof&sort=Relevance&size=10&page=1#top. Published 2017. Accessed August 21, 2017
2. Sharma M, Nazareth I, Petersen I. Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. BMJ Open. 2016;6(1):e010210
3. NHS Digital. Prescriptions Dispensed in the Community, England 2006 to 2016. Prescribing and Medicines Team, NHS Digital, UK. June 2017
4. NHS Digital. Prescribing for Diabetes, England - 2006/07 to 2016/17. http://digital.nhs.uk/catalogue/PUB30043. Published August 1, 2017. Accessed September 25, 2017
5. NICE. Algorithm for blood glucose lowering therapy in adults with type 2 diabetes. https://www.nice.org.uk/guidance/ng28/resources/algorithm-for-blood-glucose-lowering-therapy-in-adults-with-type-2-diabetes-pdf-2185604173. Published 2015. Accessed December 20, 2017
6. Herrett E, Gallagher AM, Bhaskaran K, et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827-836
7. Rodgers LR, Weedon MN, Henley WE, Hattersley AT, Shields BM. Cohort profile for the MASTERMIND study: using the Clinical Practice Research Datalink (CPRD) to investigate stratification of response to treatment in patients with type 2 diabetes. BMJ Open. 2017;7(10):e017989
8. Seidu S, Davies MJ, Mostafa S, de Lusignan S, Khunti K. Prevalence and characteristics in coding, classification and diagnosis of diabetes in primary care. Postgrad Med J. 2014;90(1059):13-17
9. Curtis HJ, Goldacre B. OpenPrescribing: normalised data and software tool to research trends in English NHS primary care prescribing 1998-2016. BMJ Open. 2018;8(2):e019921
10. Curtis HJ. Prescription Cost Analysis 1998–2016 data processing and normalisation. https://gist.github.com/HelenCEBM/192307b3c671a391f5ad6b44a3676880. Published September 28, 2017. Accessed September 28, 2017
11. Office for National Statistics. Population Estimates. ONS Statistical Bulletin. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/annualmidyearpopulationestimates/mid2016. Published June 22, 2017. Accessed September 11, 2017
12. Office for National Statistics. CPI All Items Index. ONS Time Series Data. https://www.ons.gov.uk/economy/inflationandpriceindices/timeseries/d7bt/mm23. Published September 12, 2017. Accessed September 20, 2017
13. NHS Digital. Number of Patients Registered at a GP Practice. http://content.digital.nhs.uk/gppatientsregistered. Published April 18, 2017. Accessed May 3, 2017
14. NHS Digital. Quality and Outcomes Framework (QOF) - 2016-17. http://digital.nhs.uk/catalogue/PUB30124. Published October 26, 2017. Accessed December 13, 2017
15. Curtis HJ, Goldacre B. Diabetes NHS prescribing trends 1998-2016 dataset. FigShare. February 2018. doi:https://doi.org/10.6084/m9.figshare.5873733
16. North of England CSU. Pioglitazone Memo - shortage of supply. http://medicines.necsu.nhs.uk/wp-content/uploads/2015/12/Pioglitazone_shortage_of_supply_memo_UKMi_Dec_2015.pdf. Published November 2015. Accessed October 13, 2017
17. NHS Health and Social Care Information Centre. National Diabetes Audit, Report for the Audit Period 2003/04; 2005. Available at: https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/national-diabetes-audit-2003-04. Accessed December 15, 2017
18. Qaseem A, Barry MJ, Humphrey LL, Forciea MA. Clinical Guidelines Committee of the American College of Physicians. Oral pharmacologic treatment of type 2 diabetes mellitus: A Clinical Practice Guideline update from the American College of Physicians. Ann Intern Med. 2017;166(4):279-290
19. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-149
20. American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(suppl 1):S73-S85
21. Walley T, Hughes D, Kendall H. Trends and influences on use of antidiabetic drugs in England, 1992-2003. Pharmacoepidemiol Drug Saf. 2005;14(11):769-773
22. Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab. 2016;18(4):333-347
23. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128
24. Kanavos P, van den Aardweg S, Schurer W. Diabetes Expenditure, Burden of Disease and Management in 5 EU Countries. LSE Health, London School of Economics; 2012 http://eprints.lse.ac.uk/54896/1/__libfile_REPOSITORY_Content_LSE%20Health%20and%20Social%20Care_Jan%202012_LSEDiabetesReport26Jan2012.pdf. Accessed March 9, 2018
25. Heald AH, Livingston M, Malipatil N, et al. Improving type 2 diabetes mellitus glycaemic outcomes is possible without spending more on medication: lessons from the UK National Diabetes Audit. Diabetes Obes Metab. 2018;20(1):185-194
26. Presseau J, Hawthorne G, Sniehotta FF, et al. Improving diabetes care through examining, advising, and prescribing (IDEA): protocol for a theory-based cluster randomised controlled trial of a multiple behaviour change intervention aimed at primary healthcare professionals. Implement Sci. 2014;9:61
27. Willis TA, Hartley S, Glidewell L, et al. Action to Support Practices Implement Research Evidence (ASPIRE): protocol for a cluster-randomised evaluation of adaptable implementation packages targeting “high impact” clinical practice recommendations in general practice. Implement Sci. 2016;11:25
28. Bateman DN, Good AM, Afshari R, Kelly CA. Effects of licence change on prescribing and poisons enquiries for antipsychotic agents in England and Scotland. Br J Clin Pharmacol. 2003;55(6):596-603
29. Hawton K, Bergen H, Simkin S, et al. Effect of withdrawal of co-proxamol on prescribing and deaths from drug poisoning in England and Wales: time series analysis. BMJ. 2009;338:b2270
30. Bedson J, Belcher J, Martino OI, et al. The effectiveness of national guidance in changing analgesic prescribing in primary care from 2002 to 2009: an observational database study. Eur J Pain. 2013;17(3):434-443
31. Ruscitto A, Smith BH, Guthrie B. Changes in opioid and other analgesic use 1995–2010: repeated cross-sectional analysis of dispensed prescribing for a large geographical population in Scotland. Eur J Pain. 2015;19(1):59-66
32. Nathan DM, Buse JB, Kahn SE, et al. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care. 2013;36(8):2254-2261
33. Naci H, Lehman R, Wouters OJ, Goldacre B, Yudkin JS. Rethinking the appraisal and approval of drugs for type 2 diabetes. BMJ. 2015;351:h5260